11 November 2026

Oncology Clinical Trials in South Korea: ADC Landscape

Oncology Clinical Trials in South Korea: ADC Landscape

Oncology Clinical Trials in South Korea: How In-Label IITs Speed Up ADC Evidence

South Korea’s antibody drug conjugate (ADC) market is still maturing, but its developers are attracting major global partners. In October 2025, AimedBio signed a license agreement worth up to $991 million with Boehringer Ingelheim for one of its ADCs. In October 2026, the first patient was dosed in a Phase I study of that ADC, now called BI 4060107. In December 2023, LigaChem Biosciences (formerly LegoChem Biosciences) signed a license agreement worth up to $1.7 billion with Janssen for a Trop2-directed ADC.

These deals point to where the opportunity lies: not simply in selling ADCs in Korea, but in developing them from Korea for the global market.

For oncology sponsors weighing clinical trials in South Korea, or deciding whom to partner with, the regulatory timing adds to the case. South Korea’s Ministry of Food and Drug Safety (MFDS) has set a 240-day target for the approval and review of eligible new drugs under its Medical Product Approval and Review Innovation Plan (announced in a May 28, 2026 press release), with guidelines in effect since June 1, 2026, and the full timeline applying to new applications as of October 1, 2026. Read on to understand how the ADC landscape is taking shape, what Korean clinicians want from ADC development, and where investigator-initiated trials (IITs) fit.

How South Korea’s ADC Market Is Shifting Toward Differentiation

Korean developers are entering a crowded field. Competition clusters around validated targets such as HER2, TROP2, B7-H3, and CLDN18.2, and topoisomerase I (Topo-I) payloads remain mainstream, although resistance and cross-resistance are becoming harder to ignore.

The response is a race toward next-generation designs: novel payloads, dual-payload ADCs, bispecific ADCs, and improved linkers. At the 4th Samsung Medical Center and AimedBio ADC Conference in Seoul on August 28, 2026, AimedBio’s CEO said dealmaking is continuing, but deal requirements have become more stringent and fewer targets stand out enough to win a deal. The market is moving from pipeline expansion to meaningful differentiation. A validated target is no longer enough. Sponsors need a clear answer to why their ADC is different.

Active Korean ADC Developers and Their Platforms

Korean companies are increasingly competing through platform, payload, linker, bispecific and novel-target innovation. A few examples:

Company Platform or focus Why it matters
LigaChem Biosciences ConjuALL: site-specific conjugation, β-glucuronide linker, multiple payload options Platform partnering and payload optionality
AimedBio P-ADC: patient-derived validation, AMB302 (FGFR3) and AMB303 (ROR1), out-licensed to Biohaven and SK Plasma, respectively Clinically oriented asset selection
ABL Bio / NEOK Bio Bispecific ADCs: ABL206 (B7-H3 x ROR1) and ABL209 (EGFR x MUC1) Global clinical entry, with both in U.S. Phase I
IntoCell OHPAS: flexible linker chemistry and linker-toxin library Rapid ADC candidate generation
Pinotbio PINOT-ADC: proprietary payload and linker, resistance-focused, dual-payload work Payload and linker differentiation
Genome & Company Novel-target ADCs (GENA-104 ADC, GENA-120) A novel-target strategy in a crowded field

 

Among these developers, the ABL Bio / NEOK Bio bispecifics show how far Korean ADC development already reaches beyond Korea. ABL206 (B7-H3 x ROR1) and ABL209 (EGFR x MUC1) are both in U.S. Phase I, according to public company materials.

LigaChem Biosciences and Pinotbio are competing on platform and payload. LigaChem’s ConjuALL platform combines site-specific conjugation, a β-glucuronide linker, and multiple payload options, while Pinotbio’s PINOT-ADC centers on proprietary payloads and linkers aimed at resistance. AimedBio takes a more clinical route, using patient-derived validation to select its FGFR3 and ROR1 assets, now out-licensed (to Biohaven and SK Plasma, respectively).

How AI and KDDF Funding Are Shaping Korean ADC Development

AI companies are also part of the picture. South Korea’s ADC developers are positioning themselves as innovators, not fast followers, and many are building AI into early R&D to lower clinical failure risk and development costs. Galux, for example, uses AI protein design to generate antibody sequences, and AIVIS applies AI digital pathology to quantify target antigen expression for patient selection. Three areas stand out:

Safety and precision. Computational tools predict toxicity and optimize targets before clinical trials begin. AI digital pathology and multi-omics models help identify patients most likely to respond and screen out higher-risk patients early.

Resistance. Developers are building linker and payload technology in-house, including peptide linkers engineered for plasma stability, novel payloads, and bispecific ADCs designed to block tumor escape routes. Some platforms are also designed to extend into antibody-radionuclide conjugates.

Regulatory and funding support. The Korea Drug Development Fund (KDDF) launched the ADCaptain project in 2023, bringing separate antibody, linker and payload developers together in a consortium, with ₩2.4 billion in R&D funding for an initial two-year stage. The stated goal is ADC leads for global licensing or co-development.

The MFDS’s expedited process covers new drugs, biosimilars, and innovative medical devices. Sponsors can request two or more official pre-new drug application (pre-NDA) meetings and, under the new rolling review framework, the MFDS issues first-round review opinions by category starting on day 25 (compared with roughly day 87 for the first formal deficiency notice under the old system). The agency says its goal is to get new treatments to Korean patients sooner and strengthen the market’s global competitiveness.

What Korean Oncologists Want From ADC Development

Korean oncologists, including key opinion leaders (KOLs), are asking for four things from ADC development:

Earlier-line use. ADCs are moving from late-line treatment toward first-line and earlier settings.

Long-term tolerability. This matters more as ADCs move earlier in the treatment course.

Evidence on resistance and sequencing. Clinicians need data on what to use after prior ADC exposure.

Sharper biomarker and patient selection. The right target, payload, patient and combination matter more than technology alone.

For sponsors, this is a design input, not just market color. A protocol that centers on post-ADC sequencing or a biomarker-defined population addresses what investigators already want answered.

Running Investigator-Initiated Trials (IIT) in South Korea

Korean clinicians have expressed interest in closer collaboration with biotech companies, and IITs are one way to act on it. An IIT starts with a KOL clinical question — such as an unmet need, a resistant population, a biomarker, or a sequencing problem. It generates focused exploratory evidence, and the learning informs later sponsor-led development. IITs can also explore questions or underserved populations that standard sponsor trials do not prioritize.

The main timeline variable is whether the study needs an MFDS Investigational New Drug (IND) application. An in-label IIT, using an approved drug within its approved indication, dose, and delivery route, can skip the IND step and start two to three months faster than a new-drug or off-label study. Whether a study qualifies must be checked against the Korean label: earlier-line use, new combinations, or post-ADC populations may fall outside it and require IND. Investigational assets sit on the new-drug side of that split and carry the additional regulatory gate.

Study start-up sets the pace for an IIT. Avance Clinical’s target for an in-label IIT in South Korea is first patient first visit (FPFV) in roughly three to four months, subject to site policy and study specifics. A sufficient start-up plan includes:

  • Finalizing the protocol and confirming IND exemption early.
  • Running Institutional Review Board (IRB) review and clinical trial agreement (CTA) negotiation in parallel, at about four to six weeks each.
  • Starting CTA review with the hospital’s legal or industry-academic cooperation office at IRB submission.
  • Using commercial supply through the hospital pharmacy rather than clinical labeling, which can save a month or more.

Regulatory use of IIT data depends on study design, data quality, and intended purpose, and sponsors should not assume it will be accepted.

The point is not only how fast an IIT starts, but where the evidence can take the program next. An IIT designed with the next study in mind, including a defined proof-of-concept package and a plan for how the data will be used, gives sponsors something to act on, not just a signal.

What Should Oncology Biotechs Take From This?

Know what sets your ADC apart before you plan trials in South Korea. The field rewards novel payloads, linkers, targets, and formats over another entrant on a crowded target.

Bring KOL input in early. Earlier-line use, tolerability, resistance, and biomarkers are the questions shaping Korean clinical interest.

Consider an in-label IIT for a fast, focused signal when the question involves an approved ADC used within its Korean label.

Plan beyond South Korea from the start. Early clinical evidence generated with key opinion leaders can feed a multi-country program, and the data that supports U.S. expansion, partnering, and licensing should be designed in from the first study.

Confirm program-specific requirements early with a regulatory affairs expert, especially IND exemption, how an ADC would be classified under the MFDS review process, and how IIT data will be used.

Bridging Korean ADC Innovation and Global Development

If you are planning an oncology program that includes South Korea, the goal is data that holds up with regulators and partners beyond the region. Avance Clinical’s Asia team collaborates with academic medical centers on investigator-initiated trials to help biotechs reach academic investigators and patient populations.

Through the GlobalReady model, Avance Clinical generates early-phase evidence that helps de-risk go/no-go, partnering, and licensing decisions across Asia Pacific, India, Mainland China, Australia, North America, and Europe. Full-service CRO capabilities span clinical operations, patient recruitment, data management, biostatistics, and scientific and regulatory affairs. Headquartered in Australia, the company is growing its operational and business capacity across regions, advancing clinical research partnerships to better support international drug development. That includes a July 2026 Memorandum of Understanding with the Department of Pharmaceutical and Bio-Industry, Graduate School of Dongguk University to develop clinical research talent.

Talk to Avance Clinical about how clinical trials in South Korea could fit your oncology program.

About the Author

Jessica Han

Jessica Han

Director, Asian Operations

Jessica Han's LinkedIn Profile

Read more

Related Items